Komori
General Meetings of Shareholders4503Astellas Pharma Inc.Pharmaceuticals

Partial Revision to the Notice of Convocation of the 21st Annual General Meeting of Shareholders

The figures for the TOPIX growth rate and the Company's TSR growth rate in the actual performance data for TSR ① stated in the Notice of Convocation of the 21st Annual General Meeting of Shareholders had been transposed and have been corrected. The TOPIX growth rate has been corrected from 141.0% to 197.0%, and the Company's TSR growth rate from 197.0% to 141.0%.

Worth reading
—
Scored from 0 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (21st fiscal year)
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (21st fiscal year)
Items this document does not state (5)
Date and timeMatters for resolutionShareholder ProposalDirector nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Certain matters stated in the Notice of Convocation required correction. Specifically, the figures for the TOPIX growth rate and the Company's TSR growth rate had been transposed and were corrected.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Partial Revision to the Notice of Convocation of the 21st Annual General Meeting of Shareholders | Astellas Pharma Inc. (4503) timely disclosure | Komori